Irritable%20bowel%20syndrome News

News

Mindfulness therapy reduces IBS symptoms, improves life quality

20230928110000

Mindfulness-based stress reduction therapy (MBSRT) in patients with irritable bowel syndrome (IBS) results in improved quality of life and mindfulness components, as well as reduced IBS symptoms, when compared with controls, a study has shown.

Faecal matter transplant relieves bloating in IBS

20230919060000

Faecal microbiota transplantation helps reduce abdominal bloating but not the overall symptoms in patients with irritable bowel syndrome (IBS), according to a small study.

$Faecal transplant helps teens with refractory IBS$

Faecal transplant helps teens with refractory IBS

Jairia Dela Cruz, 20230629140000

For adolescents with treatment-refractory irritable bowel syndrome (IBS), faecal microbiota transplantation (FMT) is safe and beneficial, easing abdominal pain and improving health-related quality of life, according to a study presented at ESPGHAN 2023.

Genetically predicted depression linked to multiple gastrointestinal disorders

20230531180000

Genetic predisposition to major depressive disorder has the potential to increase the risk of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcer disease, and nonalcoholic fatty liver disease (NAFLD), according to the results of a Mendelian randomization study.

COVID-19 survivors at high risk of subsequent IBS

20230421180000

Individuals who have contracted COVID-19 at increased risk of developing irritable bowel syndrome (IBS) compared with those who have not been infected, as reported in a study.

Ondansetron shows potential in irritable bowel syndrome with diarrhoea

20230327060000

A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.

Rifaximin helps improve symptoms of IBS with diarrhoea

20230321060000

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.

Mesalamine shows modest benefit in IBS

20230306060000

Treatment with mesalamine may only have modest efficacy for the global symptoms of irritable bowel syndrome (IBS), specifically IBS that causes increased diarrhoea, according to the results of a meta-analysis. However, the quality of evidence appears to be low.

Acupuncture safe, feasible in irritable bowel syndrome

20230130060000

Acupuncture appears to yield significant improvements in irritable bowel syndrome with diarrhoea (IBS-D), a study has found.

Transcutaneous electrical acustimulation effective in IBS with constipation

20220930130000

Patients with irritable bowel syndrome (IBS) and constipation (IBS-C) can improve their symptoms by undergoing transcutaneous electrical acustimulation (TEA), suggests a study. TEA speeds up colon transit and reduces rectal sensation, which is potentially mediated by using the autonomic mechanisms.

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).